ANNX Annexon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1528115 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.9%
TTM EPS YoY28.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-130.8%
ROA-83.0%
ROIC (approx.)-293.6%
Asset turnover—
Leverage & solvency
Liabilities / assets43.0%
Debt / equity0.35x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $184.70M | $119.45M | $113.76M | $112.50M | $100.07M |
| SG&A expense | $31.71M | $34.62M | $29.97M | $33.10M | $30.65M |
| Operating income | -$216.41M | -$154.07M | -$143.72M | -$145.60M | -$130.71M |
| Pretax income | -$206.69M | -$138.20M | $134.24M | $141.95M | $130.32M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$206.69M | -$138.20M | -$134.24M | -$141.95M | -$130.32M |
| EBITDA | -$214.24M | -$151.92M | -$141.57M | -$143.49M | -$128.57M |
| EPS (basic) | -1.34 | -1.01 | -1.77 | -2.60 | -3.40 |
| EPS (diluted) | -1.34 | -1.01 | -1.77 | -2.60 | -3.40 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 155.11M | 137.40M | 75.67M | 54.67M | 38.32M |
| Balance sheet | |||||
| Cash & equivalents | $162.05M | $50.53M | $226.14M | $141.05M | $76.01M |
| Short-term investments | $76.29M | $262.52M | $34.61M | $102.64M | $167.87M |
| Current assets | $242.19M | $316.46M | $263.86M | $248.10M | $247.69M |
| PP&E, net | $10.62M | $12.64M | $14.77M | $16.84M | $17.85M |
| Total assets | $277.57M | $350.07M | $297.67M | $285.10M | $287.04M |
| Current liabilities | $42.63M | $30.51M | $17.93M | $22.36M | $21.74M |
| Long-term debt | $0 | — | — | — | — |
| Total debt | $0 | — | — | — | — |
| Total liabilities | $65.92M | $56.97M | $47.12M | $53.90M | $55.13M |
| Shareholders' equity | $211.65M | $293.11M | $250.56M | $231.19M | $231.91M |
| Net debt | -$162.05M | — | — | — | — |
| Shares outstanding | 149.36M | 109.38M | 78.37M | 47.72M | 38.56M |
| Cash flow statement | |||||
| Operating cash flow | -$186.36M | -$118.01M | -$121.14M | -$116.31M | -$106.11M |
| Capital expenditure | $137,000 | $15,000 | $193,000 | $6.53M | $1.65M |
| Free cash flow | -$186.49M | -$118.02M | -$121.33M | -$122.83M | -$107.76M |
| Investing cash flow | $190.05M | -$218.80M | $70.70M | $58.44M | -$88.24M |
| Financing cash flow | $108.86M | $161.21M | $135.52M | $122.91M | $1.79M |
| Depreciation & amortization | $2.17M | $2.15M | $2.15M | $2.11M | $2.14M |
| Stock-based compensation | $16.42M | $19.43M | $18.18M | $18.52M | $16.26M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.